Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Keybanc Downgrades Kaman to Sector Weight

Keybanc Downgrades Kaman to Sector Weight

Keybanc analyst Steve Barger downgrades Kaman (NYSE:KAMN) from Overweight to Sector Weight.

byBenzinga Newsdesk

November 2, 2022

1 minute read

Keybanc analyst Steve Barger downgrades Kaman (NYSE:KAMN) from Overweight to Sector Weight.

Morgan Stanley Maintains Equal-Weight on NOV, Raises Price Target to $19

By Benzinga Newsdesk

July 29, 8:43 AM

Morgan Stanley analyst Connor Lynagh maintains NOV (NYSE:NOV) with a Equal-Weight and raises the price target from $18 to $19.

NOV

SVB Leerink Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $834

By Benzinga Newsdesk

February 6, 7:21 AM

SVB Leerink analyst David Risinger maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $770 to $834.

REGN

Why First Industrial Realty Shares Are Sliding Today

By Lekha Gupta

October 12, 12:15 PM

KeyBanc Capital Market analyst Todd M.

News

China SXT Pharmaceuticals, Inc. Receives 180-Day Extension From Nasdaq To Meet Minimum Bid Price Rule

By Happy Mohamed

May 10, 8:12 AM

China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional

SXTC

Keybanc Downgrades Kaman to Sector Weight

Related Posts

Morgan Stanley Maintains Equal-Weight on NOV, Raises Price Target to $19

SVB Leerink Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $834

Why First Industrial Realty Shares Are Sliding Today

China SXT Pharmaceuticals, Inc. Receives 180-Day Extension From Nasdaq To Meet Minimum Bid Price Rule